Macquarie Group
PETX

Macquarie Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Macquarie Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-48,920
Closed -$273K – 1620
2015
Q4 		$273K Sell
48,920
-28,911
-37% -$191K ﹤0.01% 1290
2015
Q3 		$658K Buy
+77,831
New +$1.32M ﹤0.01% 1205

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Macquarie Group's PETX Position: Q1 2016 in Review

Macquarie Group sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2016, closing a stake of 48,920 shares — an estimated $273K sold.

Macquarie Group first reported a position in PETX in Q3 2015 and held it in 2 quarters. The position peaked at $658K in Q3 2015. 95 funds tracked by Wall St. Rank hold PETX as of Q1 2016.

  • Macquarie Group reported no remaining Aratana Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Macquarie Group sold 48,920 Aratana Therapeutics, Inc. shares in Q1 2016, an estimated $273K.
  • Macquarie Group first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
  • Macquarie Group's Aratana Therapeutics, Inc. position peaked at $658K in Q3 2015.
  • 95 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2016.

Based on Macquarie Group's 13F filing for Q1 2016, filed 16 May 2016.